Argenx bid for Vyvgart label expansion undergoes FDA priority review

Argenx (ARGX) announced on Tuesday that the U.S. FDA has granted priority review for its marketing application aimed at ...
La Grande Observer

UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS ...

THOUSAND OAKS, Calif., March 13, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA ® ...
The American Journal of Managed Care

52-Week MINT Data Confirm Inebilizumab Benefit in AChR+ gMG: Richard Nowak, MD, MS

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis ...
Medscape

Alzheimer’s Disease: The Cholinergic Revival

Before the advent of the amyloid hypothesis in the 1990s, the cholinergic hypothesis offered key clues to the etiology of Alzheimer’s disease. Concentrated in the basal forebrain and projecting ...
WebMD

Rаvulizսmab (Ultomiris) for the Treatment of Generalized Myasthenia Gravis

Myasthenia gravis is an autoimmune condition that weakens the muscles in your body. Acetylcholine is a neurotransmitter that helps your muscles move. Most people with generalized myasthenia gravis ...